Variant Annotation ID	Variant/Haplotypes	Drug(s)	Phenotype Category	Significance	Sentence	Allele Of Frequency In Cases	Allele Of Frequency In Controls	P Value	Ratio Stat Type	Ratio Stat	Confidence Interval Start	Confidence Interval Stop
1451306860	CYP2C9*11	warfarin	Dosage	not stated	CYP2C9 *11/*11 is associated with decreased dose of warfarin.							
1451205960	CYP2D6*2	tramadol	Efficacy	no	CYP2D6 *2 is not associated with response to tramadol in people with Neuralgia.			= 0.467				
1451205960	CYP2D6*2	tramadol	Efficacy	no	CYP2D6 *2 is not associated with response to tramadol in people with Neuralgia.			= 0.769				
1451155580	CYP2D6 poor metabolizer	tramadol	PD	not stated	CYP2D6 poor metabolizer is associated with decreased response to tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.							
1451155685	CYP2D6 poor metabolizer phenotype	tramadol	Efficacy	yes	CYP2D6 poor metabolizer phenotype is associated with increased response to tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.			< 0.01				
1451156320	CYP2D6 poor metabolizer genotype	methadone	Efficacy	no	CYP2D6 poor metabolizer genotype is not associated with response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer genotype.							
1451156302	CYP2D6 ultrarapid metabolizer genotype	methadone	Efficacy	yes	CYP2D6 ultrarapid metabolizer genotype is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer and poor metabolizers genotypes.			= 0.003				
1451343500	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.							
1184763829	HLA-B*58:01	allopurinol	Toxicity	yes	HLA-B *58:01 is associated with decreased concentrations of allopurinol.			< 0.05	OR			
1451353708	CYP2D6 ultrarapid metabolizer	eliglustat	Dosage	not stated	CYP2D6 ultrarapid metabolizer is associated with increased dose of eliglustat in people with Gaucher Disease as compared to CYP2D6 intermediate metabolizer and normal metabolizer.							
1448276612	CYP3A5*3	tacrolimus	Dosage	not stated	CYP3A5 *3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation.	*1			OR			
1448276515	CYP4F2*3	warfarin	Dosage	not stated	CYP4F2 *3 is associated with dose of warfarin.	*3			OR			
1450928657	CYP2A6 low activity	varenicline	Efficacy	no	CYP2A6 low activity is not associated with response to varenicline in people with Tobacco Use Disorder.				HR	0.7	0.28	1.75
1450928657	CYP2A6 low activity	varenicline	Efficacy	no	CYP2A6 low activity is not associated with response to varenicline in people with Tobacco Use Disorder.				HR	0.48	0.14	1.7
1450928649	CYP2A6 high activity	varenicline	Efficacy	yes	CYP2A6 high activity is associated with increased response to varenicline in people with Tobacco Use Disorder.				HR	0.33	0.12	0.89
1450928649	CYP2A6 high activity	varenicline	Efficacy	yes	CYP2A6 high activity is associated with increased response to varenicline in people with Tobacco Use Disorder.				HR	0.45	0.2	1.0
1183849101	SLC6A4 HTTLPR short form (S allele)	paroxetine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine.			= 0.012	OR			
1451141965	NAT2 slow acetylator	hydralazine	Efficacy	not stated	NAT2 slow acetylator is associated with increased response to hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.			< 0.02				
1183619942	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	*2		= 0.15	Unknown			
1183619942	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	*2		= 0.41	Unknown			
1447519907	CYP2D6 ultrarapid metabolizer genotype	nortriptyline	Dosage	no	CYP2D6 ultrarapid metabolizer genotype are not associated with dose of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
1451125800	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clozapine	Efficacy	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are not associated with response to clozapine in people with Schizophrenia as compared to CYP2C19 normal metabolizer genotype.			= 0.120				
1451125746	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	clozapine	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with response to clozapine in people with Schizophrenia as compared to CYP2D6 normal metabolizer genotype.			= 0.738				
1451125804	CYP2C19 rapid and ultrarapid metabolizer genotypes	clozapine	Efficacy	no	CYP2C19 rapid and ultrarapid metabolizer genotypes are not associated with response to clozapine in people with Schizophrenia as compared to CYP2C19 normal metabolizer genotype.			= 0.120				
1183623333	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Ulcer.	*1		> 0.05	Unknown			
1446765775	CYP2B6*6	bupropion	Efficacy	no	CYP2B6 *6 is not associated with response to bupropion in people with Tobacco Use Disorder.			= 0.11	OR	0.64	0.38	1.08
1183685537	CYP2D6 poor metabolizer phenotype	atomoxetine	Efficacy	no	CYP2D6 poor metabolizer phenotype is not associated with response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer phenotype.				OR			
1444930545	CYP2C19*17	voriconazole	Efficacy	not stated	CYP2C19 *17/*17 is associated with decreased response to voriconazole in women with Mycoses.				OR			
1183620725	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals.	*1		= 0.150	Unknown			
1183620822	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	*1		= 0.05	Unknown			
1447814040	CYP2D6 poor metabolizers	atomoxetine	Efficacy	no	CYP2D6 poor metabolizers are not associated with response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizers.			= 0.56	OR			
1448616662	HLA-C*06:02:01:01	methotrexate	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to methotrexate in people with Psoriasis.			= 0.002	OR	2.75	1.45	5.22
1449717747	CYP2D6*4	metoprolol	Dosage	yes	CYP2D6 *4 is associated with decreased dose of metoprolol in people with Heart Failure.	*4		= 0.023	OR	0.13	0.02	0.75
1451404282	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	codeine	Efficacy	not stated	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to codeine in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.08	OR	0.35	0.14	0.84
1451406100	CYP2C8 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C8 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 normal metabolizer genotype.			= 0.129				
1451406100	CYP2C8 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C8 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 normal metabolizer genotype.			= 0.176				
1451406100	CYP2C8 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C8 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 normal metabolizer genotype.			= 0.437				
1451406100	CYP2C8 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C8 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 normal metabolizer genotype.			= 0.471				
1451406140	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C9 normal metabolizer genotype.			= 0.423				
1451406140	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C9 normal metabolizer genotype.			= 0.635				
1451406140	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C9 normal metabolizer genotype.			= 0.730				
1451406140	CYP2C9 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C9 normal metabolizer genotype.			= 0.776				
1451406240	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.053				
1451406240	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.406				
1451406240	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.620				
1451406240	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.704				
1451406173	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.516				
1451406173	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.812				
1451406173	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.828				
1451406173	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.848				
1451406220	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.454				
1451406220	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.736				
1451406220	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.832				
1451406220	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	ibuprofen	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.			= 0.971				
1451406280	CYP2D6 ultrarapid metabolizer genotype	tramadol	Efficacy	no	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			= 0.288				
1451406280	CYP2D6 ultrarapid metabolizer genotype	tramadol	Efficacy	no	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			= 0.536				
1451406280	CYP2D6 ultrarapid metabolizer genotype	tramadol	Efficacy	no	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			= 0.584				
1451406280	CYP2D6 ultrarapid metabolizer genotype	tramadol	Efficacy	no	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.			= 0.705				
1451406322	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	tramadol	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.605				
1451406322	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	tramadol	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.865				
1451406322	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	tramadol	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.936				
1451406322	CYP3A5 poor metabolizer and intermediate metabolizer genotypes	tramadol	Efficacy	no	CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with response to tramadol in people with Pain, Postoperative as compared to CYP3A5 normal metabolizer genotype.			= 0.983				
1448423400	CYP2C19*17	citalopram	Efficacy	not stated	CYP2C19 *17/*17 is associated with decreased response to citalopram in people with Obsessive-Compulsive Disorder.				OR			
1449190044	CYP2C19*17	clozapine	Efficacy	yes	CYP2C19 *17/*17 is associated with increased response to clozapine in people with schizoaffective disorder and Schizophrenia.			= 0.042	OR	4.39		
1448308386	CYP3A5*1	tacrolimus	Efficacy	yes	CYP3A5 *1/*1 is associated with decreased response to tacrolimus in people with liver transplantation.	*1		= 0.014	OR	4.322	1.34	13.95
1184348827	TPMT poor metabolizer phenotype	mercaptopurine	Dosage	not stated	TPMT poor metabolizer phenotype is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.				OR			
1184516660	TPMT intermediate activity	mercaptopurine	Efficacy	yes	TPMT intermediate activity phenotype is associated with increased response to mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT high activity phenotype.	*1		= 0.03	RR	0.3	0.1	0.88
1184747634	NAT2 slow acetylator	sulfasalazine	Other	yes	NAT2 slow acetylator is associated with increased discontinuation of sulfasalazine in people with Arthritis, Rheumatoid.			= 0.044	HR	1.74	1.01	3.21
1184747654	NAT2 slow acetylator	sulfasalazine	Efficacy	no	NAT2 slow acetylator is not associated with response to sulfasalazine in people with Arthritis, Rheumatoid.			= 0.994	OR	1.0	0.53	1.95
1448256170	CYP2D6 poor metabolizer phenotype	endoxifen	Efficacy	yes	CYP2D6 poor metabolizer phenotype is associated with decreased response to endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultra-metabolizer.			= 0.046	HR	0.4	0.16	0.99
1451477260	CYP2B6*6	methadone	Toxicity	not stated	CYP2B6 *6/*6 is associated with decreased metabolism of methadone in children with Pain, Postoperative and Scoliosis.				Unknown			
1451535546	CYP2D6 poor metabolizer and intermediate metabolizer genotypes	bisoprolol	Efficacy	no	CYP2D6 poor metabolizer and intermediate metabolizer genotypes is not associated with response to bisoprolol in people with Hypertension as compared to CYP2D6 normal metabolizer genotype.							
1451725340	CYP3A4 low activity	alprazolam	Efficacy	yes	CYP3A4 low activity is associated with increased response to alprazolam in men with Alcoholism and Anxiety Disorders as compared to CYP3A4 high activity.			= 0.003				
1451727662	CYP2D6 poor metabolizers and intermediate metabolizers	primaquine	Efficacy	no	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with decreased clinical benefit to primaquine in children with Malaria as compared to CYP2D6 normal metabolizer.							
1451727780	G6PD deficiency	primaquine	Efficacy	no	G6PD deficiency is not associated with decreased clinical benefit to primaquine in children with Malaria as compared to G6PD non-deficient.							
1451205840	CYP2D6 poor metabolizers and intermediate metabolizers	tramadol	Dosage	no	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizers.							
1451205845	CYP2D6 poor metabolizer	tramadol	Dosage	no	CYP2D6 poor metabolizer is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.			= 0.006				
1451205862	CYP2D6 ultrarapid metabolizer	tramadol	Dosage	no	CYP2D6 ultrarapid metabolizer is not associated with dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizers.							
1183680154	CYP2C19*1	esomeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.	*1		> 0.05	OR			
1183680115	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	*1		= 0.109	OR			
1183680115	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	*1		= 0.252	OR			
1447983802	CYP2A6 normal metabolizer	varenicline	Efficacy	yes	CYP2A6 normal metabolizer is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to CYP2A6 poor metabolizer.			= 0.001	OR	2.17	1.38	3.42
1447983802	CYP2A6 normal metabolizer	varenicline	Efficacy	yes	CYP2A6 normal metabolizer is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to CYP2A6 poor metabolizer.			= 0.03	OR	1.81	1.05	3.11
1447983802	CYP2A6 normal metabolizer	varenicline	Efficacy	yes	CYP2A6 normal metabolizer is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to CYP2A6 poor metabolizer.			= 0.51	OR	0.85	0.53	1.37
1447983802	CYP2A6 normal metabolizer	varenicline	Efficacy	yes	CYP2A6 normal metabolizer is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to CYP2A6 poor metabolizer.			= 0.56	OR	1.13	0.74	1.71
981954134	CYP2C9*3	acenocoumarol	Efficacy	yes	CYP2C9 *3 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.				Unknown			
1184168659	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			= 0.012	OR	8.7		
1184168659	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			= 0.02	OR	4.6		
1449577166	CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *3 is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis.				OR			
1449577192	CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *3 is associated with dose of warfarin.				OR			
1184168621	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			< 0.008	OR	13.4	1.6	12.6
1184168621	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			= 0.014	OR	3.9	2.0	7.37
1184168621	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			= 0.016	OR	4.0	1.1	8.8
1184168621	HLA-C*06:02:01:01	ustekinumab	Efficacy	yes	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.			= 0.022	OR	12.2	1.4	10.4
1448265498	CYP2C9*3	phenytoin	Dosage	yes	CYP2C9 *3 is associated with dose of phenytoin in children with Epilepsy.			< 0.001	OR			
1446904991	CYP2D6 poor metabolizers	desipramine	Dosage	not stated	CYP2D6 poor metabolizers are associated with decreased dose of desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
1448624911	CYP2C19 poor metabolizer genotype	venlafaxine	Efficacy	no	CYP2C19 poor metabolizer genotype is associated with increased response to venlafaxine in people with Depression.				OR			
1448624903	CYP2D6 ultrarapid metabolizer genotype	venlafaxine	Efficacy	no	CYP2D6 ultra-metabolizer genotype is not associated with response to venlafaxine in people with Depression as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.				OR			
1446904580	CYP2D6 poor metabolizers	nortriptyline	Dosage	no	CYP2D6 poor metabolizers are not associated with dose of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.				OR			
1184759874	HLA-B*58:01	allopurinol	Toxicity	yes	HLA-B *58:01 is associated with response to allopurinol.			< 0.05	OR			
1449296254	CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *2 is associated with decreased response to clopidogrel.			= 5.1E-40	OR			
1448267453	CYP3A5*3	tacrolimus	Dosage	no	CYP3A5 *3 is not associated with dose of tacrolimus in people with Kidney Transplantation.	*1		= 0.79	OR			
1450820529	CYP2A6 high activity	nicotine	Efficacy	yes	CYP2A6 high activity is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to CYP2A6 low activity.			= 4.41E-6	HR	0.5	0.38	0.68
1450820529	CYP2A6 high activity	nicotine	Efficacy	yes	CYP2A6 high activity is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to CYP2A6 low activity.			= 0.75	HR	0.93	0.59	1.46
1450820537	CYP2A6 high activity	bupropion	Efficacy	no	CYP2A6 high activity is not associated with response to bupropion in people with Tobacco Use Disorder as compared to CYP2A6 low activity.			= 0.022	HR	0.76	0.6	0.96
1450935426	G6PD deficiency	daunorubicin	Efficacy	no	G6PD deficiency is not associated with response to daunorubicin in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.			> 0.73				
1450935426	G6PD deficiency	daunorubicin	Efficacy	no	G6PD deficiency is not associated with response to daunorubicin in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.			= 0.78				
982032876	CYP2C9*2	acenocoumarol	Dosage	no	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.			= 0.84	Unknown			
1449002962	CYP2D6 normal metabolizer phenotype	oxycodone	Dosage	no	CYP2D6 normal metabolizer phenotype is not associated with dose of oxycodone in people with Neoplasms as compared to CYP2D6 intermediate metabolizer phenotype.			= 1	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.026	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.026	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.026	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.034	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.034	OR			
1449576707	CYP2D6 poor metabolizer genotype	tamsulosin	Efficacy	yes	CYP2D6 poor metabolizer genotype is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 intermediate metabolizer and normal metabolizer.			= 0.034	OR			
1450809758	CYP2C19 poor metabolizers	rabeprazole	Efficacy	no	CYP2C19 poor metabolizers are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 normal metabolizers.				OR			
1183623689	CYP2C19*1	esomeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.	*1		= 0.216	Unknown			
1183689724	CYP2D6 poor metabolizer	tolterodine	Efficacy	no	CYP2D6 poor metabolizer is not associated with response to tolterodine in healthy individuals as compared to CYP2D6 normal metabolizer.				OR			
1183624342	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	*1			Unknown			
1183690095	CYP2C19 poor metabolizer genotype	warfarin	Efficacy	no	CYP2C19 poor metabolizer genotype is not associated with increased response to warfarin as compared to CYP2C19 normal metabolizer genotype.	*1	*1	< 0.001	OR			
1451351660	CYP2D6 normal metabolizers	codeine	Efficacy	not stated	CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 poor metabolizers and intermediate metabolizers.							
1451351665	CYP2D6 normal metabolizers	codeine	Efficacy	not stated	CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 ultrarapid metabolizer.							
1184509840	SLC6A4 HTTLPR short form (S allele)	fluvoxamine	Efficacy	yes	SLC6A4 HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major.			= 0.010	OR			
982006752	CYP2C9*2	acenocoumarol	Dosage	no	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*2		= 0.36	Unknown			
1451155681	CYP2D6 poor metabolizer phenotype	amitriptyline	Efficacy	yes	CYP2D6 poor metabolizer phenotype is associated with decreased response to amitriptyline in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.			< 0.01				
1447944067	EPHX1 poor metabolizer	acetylcysteine	Efficacy	yes	EPHX1 poor metabolizer is associated with increased response to acetylcysteine in people with Pulmonary Disease, Chronic Obstructive as compared to genotype fast/normal (assigned as intermediate metabolizer and normal metabolizer phenotype) .			< 0.001	OR			
981940067	CYP2C9*2	acenocoumarol	Dosage	no	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*2		= 0.3	Unknown			
981940181	CYP2C9*5	acenocoumarol	Efficacy	no	CYP2C9 *5 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.	*5			Unknown			
981940163	CYP2C9*8	acenocoumarol	Efficacy	no	CYP2C9 *8 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.	*8			Unknown			
1450415150	CYP2D6 poor metabolizers	metoprolol	Dosage	yes	CYP2D6 poor metabolizers are associated with decreased dose of metoprolol.			= 0.019	OR			
1450415269	CYP2C9*3	acenocoumarol	Dosage	no	CYP2C9 *3/*3 is associated with decreased dose of acenocoumarol.				OR			
1183622426	CYP2C19*1	famotidine	Efficacy	no	CYP2C19 *1/*1 is not associated with response to famotidine in healthy individuals.	*1		= 0.05	Unknown			
1450808664	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	rabeprazole	Efficacy	yes	Genotypes *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased response to rabeprazole in people with Helicobacter Infections as compared to genotype *1/*1.			= 0.002	OR	7.129	2.054	24.746
1450808664	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	rabeprazole	Efficacy	yes	Genotypes *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased response to rabeprazole in people with Helicobacter Infections as compared to genotype *1/*1.			= 0.0376	OR	9.967	1.14	87.114
1448123532	CYP2C19 intermediate metabolizers	voriconazole	Dosage	no	CYP2C19 intermediate metabolizers are not associated with dose of voriconazole as compared to CYP2C19 normal metabolizers.			= 0.13	OR			
1448123522	CYP2C19 poor metabolizers	voriconazole	Efficacy	yes	CYP2C19 poor metabolizers are associated with increased response to voriconazole as compared to CYP2C19 normal metabolizers.			= 0.02	RR	1.31	1.04	1.67
1448123522	CYP2C19 poor metabolizers	voriconazole	Efficacy	yes	CYP2C19 poor metabolizers are associated with increased response to voriconazole as compared to CYP2C19 normal metabolizers.			= 0.07	RR	0.88	0.77	1.01
1448123522	CYP2C19 poor metabolizers	voriconazole	Efficacy	yes	CYP2C19 poor metabolizers are associated with increased response to voriconazole as compared to CYP2C19 normal metabolizers.			= 0.13	RR	1.14	0.96	1.35
1448123522	CYP2C19 poor metabolizers	voriconazole	Efficacy	yes	CYP2C19 poor metabolizers are associated with increased response to voriconazole as compared to CYP2C19 normal metabolizers.			= 0.37	RR	0.94	0.83	1.07
1450808871	CYP2A6 low activity	nicotine	Dosage	yes	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.			= 0.003	OR			
1450808871	CYP2A6 low activity	nicotine	Dosage	yes	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.			= 0.003	OR			
1450808871	CYP2A6 low activity	nicotine	Dosage	yes	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.			= 0.12	OR			
1450808871	CYP2A6 low activity	nicotine	Dosage	yes	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.			= 0.2	OR			
1450808871	CYP2A6 low activity	nicotine	Dosage	yes	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.			= 0.79	OR			
1449154360	UGT2B7	buprenorphine	Efficacy	yes	Genotype *2 is associated with decreased response to buprenorphine in people with Pain as compared to genotype *1.			< 0.05	OR			
1183622993	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1		= 0.227	Unknown			
1183622976	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1		= 0.227	Unknown			
1183622976	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1		= 0.232	Unknown			
1183622976	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1		= 0.276	Unknown			
1183622976	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1		= 0.326	Unknown			
1183688996	CYP2D6 poor metabolizer	atomoxetine	Dosage	yes	CYP2D6 poor metabolizer is associated with decreased dose of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.			< 0.05	OR			
1183688968	CYP2D6 poor metabolizer	atomoxetine	Efficacy	yes	CYP2D6 poor metabolizer is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizers.			= 0.045	OR			
1451153666	CYP2D6 poor metabolizer phenotype	oxycodone	Efficacy	not stated	CYP2D6 poor metabolizer phenotype is associated with decreased response to oxycodone in women with Neoplasms and Pain as compared to CYP2D6 normal metabolizer phenotype.							
981420009	CYP2C9*2	acenocoumarol	Dosage	not stated	CYP2C9 *2 is associated with dose of acenocoumarol in people with a stable maintence dose.	*2			Unknown			
1183634033	CYP2C19*1	lafutidine	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lafutidine in healthy individuals.	*1		> 0.05	OR			
981420013	CYP2C9*3	acenocoumarol	Dosage	not stated	CYP2C9 *3 is associated with dose of acenocoumarol in people with a stable maintence dose.	*3			Unknown			
981940074	CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*3		< 1.0E-4	Unknown			
981940169	CYP2C9*6	acenocoumarol	Efficacy	no	CYP2C9 *6 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.	*6			Unknown			
1043818268	CYP2C9*2	phenprocoumon	Dosage	no	CYP2C9 *2 is not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	*2			Unknown			
982043913	CYP2C9*2	warfarin	Dosage	yes	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 1.0E-4	Unknown			
981483891	HLA-DRB1*15:01:01:01	glatiramer acetate	Efficacy	yes	HLA-DRB1 *15:01:01:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.			= 0.0056	OR	0.072	0.002	0.28
981483891	HLA-DRB1*15:01:01:01	glatiramer acetate	Efficacy	yes	HLA-DRB1 *15:01:01:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.			= 0.013	OR	0.065	0.008	0.52
981483891	HLA-DRB1*15:01:01:01	glatiramer acetate	Efficacy	yes	HLA-DRB1 *15:01:01:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.			= 0.049	OR	0.43	0.23	0.81
981934182	CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*3		< 0.001	Unknown			
981940175	CYP2C9*11	acenocoumarol	Efficacy	no	CYP2C9 *11 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.	*11			Unknown			
981940156	CYP2C9*9	acenocoumarol	Efficacy	no	CYP2C9 *9 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.	*9			Unknown			
981934149	CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*3			Unknown			
981954118	CYP2C9*2	acenocoumarol	Efficacy	yes	CYP2C9 *2 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.				Unknown			
981865137	CYP2C9*3	acenocoumarol	Efficacy	yes	CYP2C9 *3 is associated with increased response to acenocoumarol in healthy individuals as compared to CYP2C9 *1.	*3			Unknown			
827807419	CYP2C9*1	warfarin	Dosage	yes	CYP2C9 *1/*1 is associated with increased dose of warfarin.			= 0.005	Unknown			
827824618	CYP2A6*1A	tegafur	Efficacy	no	CYP2A6 *1A is not associated with response to tegafur in people with Neoplasms.	*1A			Unknown			
1450374173	CYP2D6 poor and ultrarapid metabolizers	methadone	Dosage	no	CYP2D6 poor and ultrarapid metabolizers are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.			= 0.92	OR			
981502166	CYP2B6*6	mirtazapine	Efficacy	yes	CYP2B6 *6/*6 is associated with increased response to mirtazapine in people with Depression.			= 0.016	Unknown			
982010010	CYP2C9*1	acenocoumarol	Dosage	yes	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	*1		= 0.0011	Unknown			
981934227	CYP2C9*2	acenocoumarol	Dosage	yes	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*2		< 0.05	Unknown			
981934157	CYP2C9*2	acenocoumarol	Dosage	yes	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*2			Unknown			
982006745	CYP2C9*3	acenocoumarol	Dosage	yes	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*3		= 0.03	OR	3.4	1.41	8.34
981954438	CYP2C9*1	acenocoumarol	Dosage	no	CYP2C9 *1 is not associated with increased dose of acenocoumarol as compared to CYP2C9 *2 + *3.	*2	*3		Unknown			
982010082	CYP2C9*1	acenocoumarol	Dosage	yes	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	*1		= 0.0023	Unknown			
982015075	CYP2C9*2	acenocoumarol	Dosage	yes	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	*2		< 0.001	Unknown			
982043919	CYP2C9*3	warfarin	Dosage	yes	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.			< 1.0E-4	Unknown			
981954738	CYP2D6*3	tropisetron	Efficacy	yes	CYP2D6 *3/*3 is associated with decreased metabolism of tropisetron in people with Neoplasms.			< 0.03	Unknown			
982047473	CYP2C19*2	clopidogrel	Efficacy	yes	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	*2		= 0.04	Unknown			
982047486	CYP2C19*17	clopidogrel	Efficacy	no	CYP2C19 *17 is not associated with increased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	*17		= 0.4	Unknown			
1043818258	CYP2C9*3	phenprocoumon	Dosage	yes	CYP2C9 *3 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	*3			Unknown			
1183623682	CYP2C19*1	pantoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to pantoprazole in people with Helicobacter Infections.	*1		= 0.137	Unknown			
1183621475	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	*1			Unknown			
1183491857	CYP2C19*1	clopidogrel	Efficacy	yes	CYP2C19 *1/*1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2 + *2/*2.	*1		= 0.043	OR	2.9	1.01	8.39
1183680182	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	*1		> 0.05	OR			
1183679483	CYP2C19*1	esomeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.			= 0.414	OR	0.62	0.2	1.94
1183679483	CYP2C19*1	esomeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.			= 0.44	OR	0.64	0.21	1.98
1183679483	CYP2C19*1	esomeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.			= 0.999	OR	1.0	0.41	2.44
1183679635	CYP2C19*1	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	*1		> 0.05	OR			
1183680124	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	*1		= 0.096	OR			
1183680124	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	*1		= 0.169	OR			
1183684386	CYP2D6 poor metabolizers	imipramine	Dosage	not stated	CYP2D6 poor metabolizers are associated with decreased dose of imipramine in people with Diabetic Neuropathies as compared to CYP2D6 normal metabolizer phenotype.				OR			
1183701586	CYP2C9*6	warfarin	Dosage	no	CYP2C9 *6/*6 is associated with decreased dose of warfarin.				OR			
1183682020	CYP2D6 poor metabolizer genotype	tramadol	Dosage	no	CYP2D6 poor metabolizer genotype is associated with decreased dose of tramadol in people with Pain.			> 0.05	OR			
1183679613	CYP2C19*1	omeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	*1		> 0.05	OR			
1183679628	CYP2C19*1	lafutidine	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lafutidine in people with Helicobacter Infections.	*1		> 0.05	OR			
1183680085	CYP2C19*1	lansoprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	*1		= 0.303	OR			
1183679621	CYP2C19*1	rabeprazole	Efficacy	no	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	*1		> 0.05	OR			
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	1.27	1.18	1.36
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	1.73	1.47	2.05
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	1.2	1.1	1.31
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	1.91	1.61	2.27
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	4.88	3.05	7.8
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	clopidogrel	Efficacy	yes	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.				RR	0.99	0.84	1.17
1448267948	CYP2C9*3	warfarin	Dosage	not stated	CYP2C9 *3 is associated with dose of warfarin in people with Stroke.	*3			OR			
1449717757	CYP2D6*4	carvedilol	Dosage	no	CYP2D6 *4 is associated with increased dose of carvedilol in people with Heart Failure.	*4		= 0.093	OR	2.94	0.84	10.3
1448603449	CYP2C19 ultrarapid metabolizer genotype	pantoprazole	Efficacy	no	CYP2C19 ultra-metabolizer genotype is associated with increased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer genotype.			= 0.78	OR			
1449164047	CYP2C9 normal metabolizers	warfarin	Dosage	yes	CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers.			= 4.1E-36	OR			
1449164060	VKORC1 low activity	warfarin	Dosage	yes	VKORC1 low activity is associated with decreased dose of warfarin.			= 4.63E-72	OR			
982036531	CYP3A5*6	verapamil	Efficacy	no	CYP3A5 *6 is not associated with response to verapamil in people with Hypertension as compared to CYP3A5 *1A.				Unknown			
982036539	CYP3A5*3	verapamil	Efficacy	no	CYP3A5 *3 is not associated with response to verapamil in people with Hypertension as compared to CYP3A5 *1A.				Unknown			
982044254	CYP3A5*3	atorvastatin	Efficacy	yes	CYP3A5 *3/*3 is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1A/*1A + *1A/*3.			= 0.028	Unknown			
982044254	CYP3A5*3	atorvastatin	Efficacy	yes	CYP3A5 *3/*3 is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1A/*1A + *1A/*3.			= 0.822	Unknown			
